• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Rare Diseases

    Savara Amends Debt Facility; $75M After FDA Approval

    BUSINESSWIRE

    Savara Selects PANTHERx Rare as Exclusive U.S. Specialty Pharmacy

    BUSINESSWIRE

    Savara Resubmits BLA for Molbreevi to Treat Autoimmune PAP

    BUSINESSWIRE

    Savara To Secure EPO Patent For MOLBREEVI Liquid Formulation

    BUSINESSWIRE

    Savara Prices $130M Public Offering Of Stock And Pre-Fund Warrant

    BUSINESSWIRE

    Savara Secures $75 M Royalty Deal with RTW for Molbreevi Launch

    BUSINESSWIRE

    Savara Presents Phase 3 Impala-2 Trial Results For Molgramostim

    BUSINESSWIRE

    Savara Unveils Phase 3 Impala-2 Trial Data On Molgramostim

    BUSINESSWIRE

    Savara Reveals 50% Surge in Autoimmune PAP Patients in Latest

    PHARMAWEB

    NEJM to Publish Savara Ph 3 Impala-2 Results in Autoimmune PAP

    BUSINESSWIRE

    Savara Presents New Data on Molgramostim at ATS 2025

    BUSINESSWIRE

    Savara Reports Q1 2025 Financial Results and Business Update

    BUSINESSWIRE

    Savara to Present Molgramostim Trial Results at Conferences

    BUSINESSWIRE

    Savara Reports Q4 2024 Financial Results and Business Update

    BUSINESSWIRE

    Savara to Present New Data From Phase 3 Trial at ATS 2025

    BUSINESSWIRE

    Savara Launches aPAP ClearPath™ Blood Test For Autoimmune aPAP

    BUSINESSWIRE

    Savara Begins BLA Submission for MOLBREEVI in aPAP Treatment

    BUSINESSWIRE

    Savara backs talk show episode to boost rare disease awareness

    FIERCE PHARMA

    Savara`s aPAP Highlighted On “The Balancing Act®” Airing

    BUSINESSWIRE

    Savara Presents IMPALA-2 Trial Data On Molgramostim For aPAP At ERS

    BUSINESSWIRE

    Savara Announces New Employment Inducement Grant

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.